Spots Global Cancer Trial Database for metastatic melanoma
Every month we try and update this database with for metastatic melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma | NCT00256282 | Metastatic Mela... | Vinorelbine Docetaxel Sargramostim | 18 Years - | University of California, Irvine | |
| RAD001 Plus Bevacizumab in Metastatic Melanoma | NCT00591734 | Metastatic Mela... | Bevacizumab Everolimus | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer | NCT00095108 | Melanoma Kidney Neoplasm... Metastases | Recombinant Hum... | 18 Years - | ZymoGenetics | |
| A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | NCT00434252 | Melanoma | bevacizumab carboplatin paclitaxel placebo | 18 Years - | Genentech, Inc. | |
| Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. | NCT02678741 | Metastatic Mela... | TLPLDC Vaccine | 18 Years - | Elios Therapeutics, LLC | |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | NCT02062359 | Metastatic Canc... Metastatic Mela... | Anti-NY ESO-1 T... Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | NCT03474497 | Non Small Cell ... Metastatic Mela... Metastatic Rena... Head and Neck S... | IL-2 Pembrolizumab Radiotherapy | 18 Years - | University of California, Davis | |
| A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma | NCT03153085 | Melanoma Stage ... Melanoma Stage ... | TBI-1401(HF10) Ipilimumab | 20 Years - | Takara Bio Inc. | |
| A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas | NCT02375984 | Metastatic Mela... | Tumor Infiltrat... | 18 Years - | Saint John's Cancer Institute | |
| Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma | NCT01216436 | Metastatic Mela... | Vaccination wit... | 18 Years - | Duke University | |
| A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients | NCT02619058 | Melanoma | NKT cells | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
| High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | NCT01266603 | Melanoma | HDIL-2 recMAGE-A3 + AS... | 18 Years - | M.D. Anderson Cancer Center | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | NCT04140526 | Non Small Cell ... Advanced Solid ... Metastatic Mela... Metastatic Head... Metastatic Rena... Metastatic Colo... Sarcomas Metastatic Pros... Ovarian Cancer Small Cell Lung... Metastatic Brea... Pancreas Cancer Gastric Cancer Esophageal Canc... Gastroesophagea... Cervical Cancer Adenoid Cystic ... Salivary Gland ... Urothelial Carc... | ONC-392 Pembrolizumab Docetaxel | 18 Years - | OncoC4, Inc. | |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02097225 | BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So... | Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma | NCT01216436 | Metastatic Mela... | Vaccination wit... | 18 Years - | Duke University | |
| Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | NCT02013492 | Male Breast Can... Recurrent Melan... Stage IV Breast... Stage IV Melano... Stage IV Ovaria... Stage IV Ovaria... Unspecified Adu... Hepatocellular ... | propranolol hyd... Correlative Stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma | NCT01009775 | Melanoma | YM155 Docetaxel | 18 Years - | Astellas Pharma Inc | |
| Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | NCT00665470 | Skin Cancer Metastatic Mela... | Aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists | NCT02126579 | Melanoma Metastatic Mela... Mucosal Melanom... | Peptide Vaccine... PolyICLC Resiquimod IFA | 18 Years - | University of Virginia | |
| Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy | NCT03888950 | Metastatic Mela... | FDG PET-CT | 18 Years - | Centre Hospitalier Universitaire de Nice | |
| Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma | NCT05470283 | Tumor Metastatic Mela... Melanoma | OBX-115 Acetazolamide Cyclophosphamid... Furosemide Mesna Fludarabine Pho... | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma | NCT00881049 | Metastatic Mela... | Imatinib (Gleev... | 18 Years - 85 Years | Peking University | |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | NCT02073123 | Metastatic Mela... Stage III Melan... Stage IV Melano... | Indoximod Ipilimumab Nivolumab Pembrolizumab | 18 Years - | Lumos Pharma | |
| Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | NCT03864042 | Advanced Solid ... Metastatic Mela... | losartan dextromethorpha... caffeine omeprazole midazolam rosuvastatin bupropion immed... encorafenib binimetinib modafinil | 18 Years - | Pfizer | |
| Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases | NCT05341349 | Clinical Stage ... Melanoma of Unk... Metastatic Mali... Metastatic Mela... Metastatic Muco... Metastatic Ocul... Pathologic Stag... | Ipilimumab Nivolumab Pembrolizumab Stereotactic Ra... Tumor Treating ... | 22 Years - | Emory University | |
| Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | NCT02141542 | Metastatic Mela... | Tremelimumab MEDI3617 | 18 Years - | Dana-Farber Cancer Institute | |
| Melanoma Biomarker Study | NCT00348088 | Metastatic Mela... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | ||
| BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma | NCT02872259 | Melanoma | BGB324+pembroli... BGB324+dabrafen... pembrolizumab dabrafenib and ... | 18 Years - | Haukeland University Hospital | |
| Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | NCT01689870 | Metastatic Mela... | Anti-OX40 Ipilimumab | 18 Years - | Ludwig Institute for Cancer Research | |
| Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain | NCT02039947 | Melanoma and Br... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma | NCT02581930 | Metastatic Mela... Recurrent Cutan... Stage IV Cutane... | Ibrutinib Laboratory Biom... Pharmacogenomic... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of LN-144 in People With Metastatic Melanoma to the Brain | NCT05640193 | Metastatic Mela... | Lifileucel (LN-... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | NCT05848739 | Breast Cancer M... Pancreatic Canc... NSCLC, Metastat... Synovial Sarcom... Colon Cancer Metastatic Colo... Melanoma Recurr... Metastatic Skin... Melanoma Stage ... Triple Negative... TNBC - Triple-N... Cholangiocarcin... Ovarian Cancer Metastatic Mela... Hepatocellular ... | ST316 | 18 Years - | Sapience Therapeutics | |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | NCT04752267 | Anatomic Stage ... Clinical Stage ... Glioma Malignant Brain... Metastatic Brea... Metastatic Colo... Metastatic Kidn... Metastatic Lung... Metastatic Mali... Metastatic Mela... Pathologic Stag... Prognostic Stag... Stage IV Colon ... Stage IV Lung C... Stage IV Renal ... Stage IVA Colon... Stage IVA Lung ... Stage IVB Colon... Stage IVB Lung ... Stage IVC Colon... | Computed Tomogr... 18F-FMAU Multiparametric... Positron Emissi... | 18 Years - | University of Southern California | |
| Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | NCT01369875 | Metastatic Mela... Skin Cancer | Cyclophosphamid... Fludarabine Aldesleukin Tumor Infiltrat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | NCT02858869 | Metastatic Mali... Metastatic Mela... Mucosal Melanom... Ocular Melanoma Stage IV Non-Sm... Stage IV Skin M... Melanoma of Unk... | Pembrolizumab Stereotactic Ra... | 18 Years - | Emory University | |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | NCT01902173 | Hematopoietic a... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Stage IIIC Cuta... Stage IV Cutane... Unresectable Ma... Unresectable Me... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Magnetic Resona... Trametinib Dime... Uprosertib | 18 Years - | National Cancer Institute (NCI) | |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | NCT01218867 | Metastatic Canc... Metastatic Mela... Renal Cancer | Anti-VEGFR2 CAR... Cyclophosphamid... Aldesleukin Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma | NCT03803397 | Metastatic Mela... | PV-001-DC | 18 Years - | PrimeVax Immuno-Oncology Inc. | |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | NCT03123783 | Cancer Non Small Cell ... Metastatic Mela... Neoplasm of Lun... Melanoma | APX005M Nivolumab | 18 Years - | Apexigen America, Inc. | |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | NCT02910700 | Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me... | Binimetinib Dabrafenib Encorafenib Laboratory Biom... Nivolumab Pharmacological... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma | NCT03013101 | Advanced Melano... Metastatic Mela... | humanized anti-... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | NCT00314106 | Metastatic Mela... | Melanoma Reacti... Cyclophosphamid... IL-2 Fludarabine 1200 total body... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | NCT00402662 | Metastatic Mela... | everolimus Imatinib | 18 Years - | Yale University | |
| PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy | NCT01415167 | Metastatic Rena... Metastatic Mela... | 18 Years - | Prometheus Laboratories | ||
| Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 | NCT01216696 | Metastatic Mela... | ipilimumab | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| A Novel Treatment for Metastatic Melanoma | NCT00758797 | Metastatic Mela... | Photoimmunother... | 18 Years - | Northwestern University | |
| Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients | NCT06369428 | Metastatic Mela... | 18 Years - | Novartis | ||
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | NCT04511013 | Acral Lentigino... Clinical Stage ... Metastatic Cuta... Metastatic Mali... Metastatic Mela... Metastatic Muco... Pathologic Stag... | Binimetinib Encorafenib Ipilimumab Nivolumab | 18 Years - | SWOG Cancer Research Network | |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | NCT02419495 | Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re... | Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | NCT03122522 | Metastatic Mela... | ipilimumab nivolumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | NCT04109456 | Metastatic Mela... | IN10018 Cobimetinib Atezolizumab | 18 Years - | InxMed (Shanghai) Co., Ltd. | |
| Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | NCT03865212 | Clinical Stage ... Clinical Stage ... Metastatic Chor... Metastatic Mela... Metastatic Muco... Metastatic Uvea... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Unresectable Me... | Recombinant Ves... | 18 Years - | Mayo Clinic | |
| Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma | NCT03225365 | Metastatic Mela... | Blood and biops... | 18 Years - | Hospices Civils de Lyon | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention | NCT03817125 | Metastatic Mela... | Placebo for ant... Vancomycin pret... Nivolumab Matching Placeb... SER-401 | 18 Years - | Parker Institute for Cancer Immunotherapy | |
| Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma | NCT01933061 | Metastatic Mela... | Abraxane Abraxane | 18 Years - | Celgene | |
| Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma | NCT00609011 | Metastatic Mela... | MPC-6827 + Temo... | 18 Years - | Myrexis Inc. | |
| Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | NCT01340729 | Metastatic Mela... | TPI 287 | 15 Years - | M.D. Anderson Cancer Center | |
| Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | NCT04557956 | Clinical Stage ... Metastatic Mela... | Biopsy Computed Tomogr... Dabrafenib Mesy... Echocardiogram ... Magnetic Resona... Multigated Acqu... Tazemetostat Hy... Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| RAD001 Plus Bevacizumab in Metastatic Melanoma | NCT00591734 | Metastatic Mela... | Bevacizumab Everolimus | 18 Years - | SCRI Development Innovations, LLC | |
| Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | NCT04588246 | Anatomic Stage ... Metastatic Brea... Metastatic Dige... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Prognostic Stag... Recurrent Brain... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... | Memantine Quality-of-Life... Questionnaire A... Stereotactic Ra... Whole-Brain Rad... | 18 Years - | NRG Oncology | |
| Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | NCT03025256 | Acral Lentigino... Central Nervous... Clinical Stage ... Leptomeningeal ... Melanocytoma Metastatic Lung... Metastatic Mela... Metastatic Muco... Metastatic Uvea... Stage IV Lung C... | Biospecimen Col... Computed Tomogr... Lumbar Puncture Magnetic Resona... Nivolumab Positron Emissi... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | NCT02302339 | Melanoma | glembatumumab v... glembatumumab v... glembatumumab v... glembatumumab v... | 18 Years - | Celldex Therapeutics | |
| Post-ATU Study of Nivolumab | NCT03325257 | Melanoma | Routine care | 18 Years - | Nantes University Hospital | |
| Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | NCT03590054 | Stage III Cutan... Stage IV Cutane... Locally Advance... Locally Advance... Metastatic Head... Metastatic Mali... Metastatic Mela... Metastatic Urot... Non-Small Cell ... Stage IB Lung C... Stage III Cutan... Stage III Lung ... Stage III Urete... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Cutane... Stage IV Lung C... Stage IV Ureter... Stage IVA Lung ... Stage IVB Lung ... | Abexinostat Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | NCT01014351 | Metastatic Mela... | Paclitaxel Carboplatin Everolimus | 18 Years - | SCRI Development Innovations, LLC | |
| Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | NCT02631447 | Metastatic Mela... | LGX818 MEK162 Nivolumab Ipilimumab | 18 Years - | Fondazione Melanoma Onlus | |
| Radiotherapy & Combi in Metastatic Melanoma | NCT02392871 | Metastatic Mela... | Palliative radi... Dabrafenib and ... | 18 Years - | Melanoma and Skin Cancer Trials Limited | |
| Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | NCT00512889 | Melanoma (Skin) | therapeutic aut... Use of an artif... GM-CSF Irradiation of ... | 18 Years - | Dana-Farber Cancer Institute | |
| Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma | NCT00226473 | Metastatic Mela... | Cisplatin, Vind... | 18 Years - 75 Years | Dermatologic Cooperative Oncology Group | |
| A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | NCT03445533 | Metastatic Mela... | Ipilimumab Tilsotolimod wi... | 18 Years - | Idera Pharmaceuticals, Inc. | |
| Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | NCT01989585 | Clinical Stage ... Clinical Stage ... Malignant Solid... Metastatic Mela... Unresectable Me... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Navitoclax Pharmacological... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma | NCT02644967 | Metastatic Mela... | IMO-2125 Ipilimumab | 18 Years - | Idera Pharmaceuticals, Inc. | |
| Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | NCT06151847 | Clinical Stage ... Metastatic Mela... Pathologic Stag... Unresectable Me... | Biospecimen Col... Cyclophosphamid... Echocardiograph... Fludarabine Interleukin-2 Lifileucel Magnetic Resona... Multigated Acqu... Tumor Resection | 18 Years - 70 Years | University of Kansas Medical Center | |
| Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases | NCT05341349 | Clinical Stage ... Melanoma of Unk... Metastatic Mali... Metastatic Mela... Metastatic Muco... Metastatic Ocul... Pathologic Stag... | Ipilimumab Nivolumab Pembrolizumab Stereotactic Ra... Tumor Treating ... | 22 Years - | Emory University | |
| Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | NCT04771520 | Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Metastatic Prim... Metastatic Sarc... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Prognostic Stag... Prognostic Stag... Stage IIIC Colo... Stage IIIC Lung... Stage IV Colore... Stage IV Lung C... Stage IVA Color... Stage IVA Lung ... Stage IVB Color... Stage IVB Lung ... Stage IVC Color... | Avapritinib | 18 Years - | M.D. Anderson Cancer Center | |
| Vaccination Plus Ontak in Patients With Metastatic Melanoma | NCT00515528 | Melanoma | 4-peptide melan... Ontak | 18 Years - | University of Chicago | |
| Dose Escalation Study of MLN4924 in Adults With Melanoma | NCT01011530 | Metastatic Mela... | MLN4924 | 18 Years - | Millennium Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
